Herpes zoster (shingles) complicating the course of COVID19 infection

Elsaie, Mohamed L.; Nada, Hesham

doi:10.1080/09546634.2020.1782823

Cited by 32 publications

(35 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Albeit several hypotheses on pathophysiological mechanisms at the basis of these skin findings are present in the literature [50, 92, 93], none of them is substantiated by strong evidence, and this field needs to be largely elucidated. Moreover, cutaneous eruptions due to viruses other than SARS-CoV-2 [35, 37] or drugs prescribed for the management of this infection [94, 95] always need to be ruled out.…”

Section: Resultsmentioning

confidence: 99%

“…Tammaro et al [34] described the onset of numerous, isolated vesicles on the back 8 days after COVID-19 diagnosis in a Barcelonan woman and reported on 2 patients from Rome presenting with isolated, mildly pruritic erythematous-vesicular lesions on their trunk, speculating that these manifestations might be due to viruses belonging to the Herpesviridae family. On the other hand, classic herpes zoster has been reported to complicate the course of COVID-19 [35].…”

Section: Papulovesicular Exanthemmentioning

confidence: 99%

See 1 more Smart Citation

Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives

et al. 2020

View full text Add to dashboard Cite

Background: Coronavirus disease-19 (COVID-19) is an ongoing global pandemic caused by the “severe acute respiratory syndrome coronavirus 2” (SARS-CoV-2), which was isolated for the first time in Wuhan (China) in December 2019. Common symptoms include fever, cough, fatigue, dyspnea and hypogeusia/hyposmia. Among extrapulmonary signs associated with COVID-19, dermatological manifestations have been increasingly reported in the last few months. Summary: The polymorphic nature of COVID-19-associated cutaneous manifestations led our group to propose a classification, which distinguishes the following six main clinical patterns: (i) urticarial rash, (ii) confluent erythematous/maculopapular/morbilliform rash, (iii) papulovesicular exanthem, (iv) chilblain-like acral pattern, (v) livedo reticularis/racemosa-like pattern, (vi) purpuric “vasculitic” pattern. This review summarizes the current knowledge on COVID-19-associated cutaneous manifestations, focusing on clinical features and therapeutic management of each category and attempting to give an overview of the hypothesized pathophysiological mechanisms of these conditions.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Papulovesicular Exanthemmentioning

confidence: 99%

Skin Manifestations Associated with COVID-19: Current Knowledge and Future Perspectives

et al. 2020

View full text Add to dashboard Cite

show abstract

“…4 The findings described can mimic other acantholytic disorders such as autoimmune or familial pemphigus or Grover transient acantholytic dermatosis 5 and it is important to exclude herpetic infection. 6,7 Purpuric and livedoid lesions…”

Section: Vesicular Exanthemmentioning

confidence: 99%

Skin manifestations of COVID‐19 in children: Part 3

et al. 2020

View full text Add to dashboard Cite

Summary The current COVID‐19 pandemic is caused by the SARS‐CoV‐2 coronavirus. The initial recognized symptoms were respiratory, sometimes culminating in severe respiratory distress requiring ventilation, and causing death in a percentage of those infected. As time has passed, other symptoms have been recognized. The initial reports of cutaneous manifestations were from Italian dermatologists, probably because Italy was the first European country to be heavily affected by the pandemic. The overall clinical presentation, course and outcome of SARS‐CoV‐2 infection in children differ from those in adults as do the cutaneous manifestations of childhood. In this review, we summarize the current knowledge on the cutaneous manifestations of COVID‐19 in children after thorough and critical review of articles published in the literature and from the personal experience of a large panel of paediatric dermatologists in Europe. In Part 1, we discuss one of the first and most widespread cutaneous manifestations of COVID‐19, chilblain‐like lesions, and in Part 2 we expanded to other manifestations, including erythema multiforme, urticaria and Kawasaki disease‐like inflammatory multisystemic syndrome. In this part of the review, we discuss the histological findings of COVID‐19 manifestations, and the testing and management of infected children for both COVID‐19 and any other pre‐existing conditions.

show abstract

“…The only abnormality was a slight ESR and a C-reactive protein (CRP) elevation [18]. Another 44-year-old male from Egypt developed zoster, about a week after he was diagnosed with mild COVID-19 infection [24].…”

Section: Clinical Features and Epidemiologymentioning

confidence: 99%

“…The pain and fever subsided on taking analgesics and anti-inflammatory medications-acetaminophen, tramadol, and gabapentin. [18,19,21,22,24,25]. However, in others, oral steroids [19] were also prescribed.…”

Section: Treatment and Prognosismentioning

confidence: 99%